Skip to main content
. 2024 Dec 30;79:103870. doi: 10.1016/j.breast.2024.103870

Table 3a.

Demographic and tumor details of the included participants from cohort studies.

Study ID Pts demographics
 Tumor details
No. of pts Mean pts age (range) Pts sex M/F Presentation: Primary or Recurrent Baseline functional status Median tumor size (cm) Metastases (no. of pts) Tumor histology (no. of pts) TNM status (no. of pts) Receptor status (no. of pts and/or %)
Abdallah (2022) 82 60.8 ± 14.2 (31–86)

  • M 2

  • F 80

  • -Primary 82

 NR 5.5 (2–20) 54/78

  • -DCIS 1

  • -IDC 70

  • -ILC 3

  • -Mixed 1

  • -Mucinous 2

  • -Medullary 1

  • -Undifferentiated 1

  • -Metaplastic 1

  • -Intracystic papillary with invasion 1

  • -IIb 1

  • -IIIa 1

  • -IIIb 15

  • -IIIc 7

  • -IV54

  • -ER− 25/69

  • -ER+ 44/69

  • -PR− 27/68

  • -PR+ 41/68

  • -HER2 = 3 + 20/63
Andersen (2009) 11 61 (47–72) F 3 other NR

  • -Primary 1

  • -Recurrent 10

 NR NR NR

  • -Adenocarcinoma 1

  • -Carcinoma 3

  • -Sol. scirrhous carcinoma 3

  • -Sol. carcinoma 1

  • Intracanal carcinoma 1

 NR NR
Bichoo (2020) 79 55 ± 11 (35–86) of all pts

  • F 76

  • M 3

  • -Primary 70

  • -Recurrent 9

 NR 7.6 ± 2.8 33

  • -IDC 73

  • -ILC 1

  • Mucinous carcinoma 1

  • -IDC with neuroendocrine differentiation 1

  • -IDC with sarcomatoid differentiation 1

  • -Invasive papillary carcinoma 1

  • -Secretory carcinoma 1

  • -IIIB 44

  • -IIIC 2

  • -IV33

  • -HR+ 44 %

  • -HER2 = 3 + 40 %

  • -TNBC 32 %
Chia (2016) 35 59 (40–91) NR NR

  • -ECOG 0–1 = 28

  • -ECOG ≥2 = 4

  • -NR = 3

 NR 9 NR NR NR
Hoeltgen (2023) 26 61 (25–83) NR Primary and recurrent but the no. of pts was NR

  • ECOG 0 17.4 %

  • ECOG 1 52.2 %

  • ECOG 2 17.4 %

  • ECOG 3 8.7 %

  • ECOG 4 4.3 %

 NR 23 NR NR

  • -HR+, HER2− 44.0 %

  • -HR+, HER2 = 3 + 12.0 %

  • -HR−, HER2 = 3 + 12.0 %

  • -HR−, HER2− 32.0 %
Kakagia (2004) 4 NR (67–83) NR

  • -Primary 4

 NR NR None

  • IDC 4

 NR

  • -ER+ 100 %
La Verde (2013) 23 63 (31–86) NR

  • -Recurrent 23

 median KPS 90 (50–100) NR 23

  • -IDC 20

NR 1 other histologies 2		 NR

  • -ER+ 9

  • -ER− 9

  • -PR+ 8

  • -PR− 10

  • -HER2− 16

  • -HER2 = 3 + 2
Merino (2015) 47 60 (30–89) NR

  • -Recurrent 47

 NR 6.5 NR NR NR

  • -ER+ 21

  • -PR+ 12

  • -NR 14
Shaugnessy (2015) 20 57 (39–85) NR

  • -Primary 9

  • -Recurrent 11

 NR NR 11 IDC 20 NR

  • -ER+ 60 %

  • -PR+ 30 %

  • -HER2 = 3 + 20 %
Vempati (2016) 13 64 (34–95) F NR NR NR NR NR NR

  • -ER+, PR+, HER2−: 4 (RT-naïve group)

  • -ER+, PR−, HER2−: 2 (prior RT group), 1 (RT-naïve group)

  • -ER−, PR−, HER2−: 4 (prior RT group), 2 (RT-naïve group)

Data are reported when available as number (%) or mean (range). Abbreviations: M:male, F:female, pts: patients, DCIS: ductal carcinoma in situ, IDC: infiltrating ductal carcinoma, ILC: infiltrating lobular carcinoma, NR: not reported, ECOG: eastern cooperative oncology group, HR: hormone receptor, ER: estrogen receptor, PR: progesterone receptor, HER2: human epidermal growth factor receptor 2, RT: radiotherapy treatment.